|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.50 SEK | +0.39% |
|
+5.23% | -30.62% |
| 23/06 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 18/06 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
| Market Cap | 82Cr 8.46Cr 7.42Cr 6.84Cr 6.4Cr 12Cr 797.87Cr 12Cr 32Cr 394.33Cr 32Cr 31Cr 1.37TCr | P/E 2026 * |
-10.4x | P/E 2027 * | -20.3x |
|---|---|---|---|---|---|
| Enterprise Value | 80Cr 8.28Cr 7.26Cr 6.69Cr 6.26Cr 12Cr 780.9Cr 12Cr 31Cr 385.94Cr 31Cr 30Cr 1.34TCr | EV / Sales 2026 * |
5.8x | EV / Sales 2027 * | 40x |
| Free-Float |
70.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: SynAct Pharma AB
| 1 day | +1.55% | ||
| 1 week | +5.23% | ||
| Current month | -9.99% | ||
| 1 month | -9.99% | ||
| 3 months | -12.60% | ||
| 6 months | -31.97% | ||
| Current year | -30.62% |
| 1 week | 13.98 |  | 16.38 |
| 1 month | 7.05 | | 18.2 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 124.6 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.75 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 01/01/2014 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 01/03/2026 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 15/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Sten Scheibye
BRD | Director/Board Member | 74 | 20/03/2024 |
Anders Kronborg
CHM | Chairman | 62 | 20/03/2024 |
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 20/03/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/03 | Buy | Chairman | 2,750 | 0.0052% | ||
| 09/03 | Buy | Executive/Senior Manager | 1,500 | 0.0028% | ||
| 09/03 | Quantass ApS
| Buy | Company | 7,900 | 0.0148% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.39% | +5.23% | -18.16% | -78.07% | 8.46Cr | |
| +7.13% | +9.97% | +55.80% | +163.38% | 1,07700Cr | |
| +3.99% | +11.50% | +67.09% | +56.27% | 61TCr | |
| +4.20% | +17.03% | +38.97% | +91.19% | 45TCr | |
| +0.13% | +4.85% | +28.17% | +22.04% | 33TCr | |
| -0.24% | +8.13% | +42.00% | +27.89% | 29TCr | |
| -0.63% | +4.64% | +30.87% | +41.21% | 29TCr | |
| -1.19% | +4.58% | -28.64% | -41.19% | 21TCr | |
| +1.56% | +6.14% | +29.30% | +61.91% | 19TCr | |
| +3.26% | +3.33% | +15.55% | +67.87% | 16TCr | |
| Average | +1.98% | +10.87% | +26.09% | +41.25% | 36.16TCr | |
| Weighted average by Cap. | +3.43% | +9.65% | +41.80% | +80.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 14Cr 1.43Cr 1.25Cr 1.15Cr 1.08Cr 2.03Cr 134.74Cr 2.07Cr 5.37Cr 67Cr 5.36Cr 5.25Cr 230.91Cr | 2.12Cr 21.77L 19.09L 17.6L 16.47L 30.89L 21Cr 31.53L 81.84L 10Cr 81.76L 79.97L 35Cr |
| Net income | 5.22Cr 53.71L 47.09L 43.41L 40.64L 76.21L 51Cr 77.79L 2.02Cr 25Cr 2.02Cr 1.97Cr 87Cr | -2.6Cr -26.81L -23.51L -21.67L -20.29L -38.04L -25Cr -38.83L -1.01Cr -12Cr -1.01Cr -98.48L -43Cr |
| Net Debt | -1.75Cr -17.99L -15.78L -14.54L -13.62L -25.53L -17Cr -26.06L -67.64L -8.39Cr -67.57L -66.09L -29Cr | 2.49Cr 25.59L 22.44L 20.68L 19.36L 36.31L 24Cr 37.06L 96.19L 12Cr 96.1L 94L 41Cr |
Employees
8
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | SEK 15.50 | +0.39% | 13,830 |
| 26/26/26 | SEK 15.44 | +0.92% | 1,89,143 |
| 25/26/25 | SEK 15.30 | +1.59% | 2,56,366 |
| 24/26/24 | SEK 15.06 | -0.92% | 2,65,235 |
| 23/26/23 | SEK 15.20 | +2.01% | 4,54,040 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Select your edition
All financial news and data tailored to specific country editions
